Sunshine Biopharma Inc. — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012. The company describes itself as a development-stage pharmaceutical business focused on cancer drug research and development. The interim financial statements are unaudited.
Financial results and liquidity
- Revenue: $0, unchanged from Q1 2011.
- Net loss: $39,341, versus $49,216 in Q1 2011, an improvement of $9,875 (about 20%). Basic loss per share was reported as $0.00, or less than $0.01; weighted-average shares were 48,728,842 versus 30,677,674.
- Expenses: General and administrative expenses were $39,325, down from $49,216. Q1 2012 included $25,000 in financial consulting fees; Q1 2011 included $15,119 in public-relations costs and $17,650 in research and development costs, none of which were incurred in Q1 2012.
- Cash flow: Operating activities used $34,757, compared with $44,330 in Q1 2011. Investing cash flow was $0. The cash-flow statement reports $12,500 of financing from a note payable; see disclosure inconsistency below.
- Cash and liquidity: Cash was $38,435 at March 31, 2012, down from $60,692 at December 31, 2011. Current assets were $84,180 and current liabilities $20,518, implying working capital of $63,662.
- Debt: A $12,500 note payable bears 12% interest and matures August 31, 2012. Interest payable was $16. Total liabilities were $20,518.
- Equity and accumulated losses: Shareholders’ equity was $63,662; accumulated deficit was $2,334,055. Common shares issued and outstanding were 48,728,842 at March 31 and May 8, 2012.
- Margins: Not meaningful because the company had no revenue.
Business developments, outlook and risks
- The company reported completing early preclinical studies of its lead candidate, Adva-27a, in 2011. Its stated next steps were GMP manufacturing, IND-enabling studies, regulatory filing and Phase I trials for multidrug-resistant breast cancer.
- Management expected Phase I trials to begin in late 2013, if sufficient funding was obtained, and anticipated completing trials by late 2014. These are forward-looking plans, not confirmed milestones. The company had an agreement with McGill University’s Jewish General Hospital to conduct Phase I trials.
- The filing describes preclinical findings for Adva-27a, including activity against multidrug-resistant breast cancer cells. These are company-reported preclinical results and do not establish clinical safety or effectiveness.
- The company reported no operating revenue since inception and said it expects further losses. It estimated that approximately $5 million in debt and/or equity capital would be needed to implement its business plan; as of the report date, it had no financing agreement for that amount. It planned to seek private-placement proceeds, short-term borrowing and grants.
- The filing states that limited current operations are expected to become more costly as research and development and clinical trials advance, and that existing funds are insufficient for anticipated increases. It identifies substantial doubt about the company’s ability to continue as a going concern.
- Management said disclosure controls were effective at a reasonable-assurance level and reported no material changes in internal control over financial reporting during the quarter. The filing lists no legal proceedings or unregistered equity sales.
Most important facts for investors to verify
- The MD&A says financing cash flows were $0 in Q1 2012, but the cash-flow statement reports $12,500 of proceeds from a note payable. Confirm the correct disclosure and note terms.
- Confirm cash runway, near-term obligations and the status and terms of any financing; the filing says the company needed substantial additional capital and had no committed funding for its estimated $5 million requirement.
- Check progress and funding for Adva-27a’s manufacturing, IND-enabling work, regulatory steps and proposed Phase I trials against the stated timelines.
- Assess the basis and limitations of the reported preclinical results; the filing provides no clinical efficacy or safety results.
- Review the going-concern warning and the company’s ability to fund operations as expenses increase.